

MAPPING EUROPE'S OLIGONUCLEOTIDE & PEPTIDE INDUSTRY

80+ Biopharma Companies,
Academics & CDMOs
Across **7** European Regions

UK

Ireland

DACH

Benelux

France

Italy & Spain

Nordics

prepared in conjunction with

Oligos & Peptides
Manufacturing DACH 2027

&

Oligos & Peptides
Manufacturing Europe 2027

co-located with

co-located with



BIOLOGICS
MANUFACTURING
IRELAND 2027

BIOLOGICS
MANUFACTURING DACH 2027

CGT MANUFACTURING
DACH 2027



Oligonucleotides, peptides, mRNA, RNA therapeutics and gene-based medicines are no longer niche modalities sitting alongside traditional small molecules and biologics. They are shaping investment decisions, redrawing manufacturing networks and pushing pharmaceutical companies, biotechs and CDMOs to rethink where and how they build capacity.

This eBook maps 80+ Biopharma Companies, CDMOs & Academics across seven of Europe's most important hubs: the UK, Ireland, DACH, Benelux, France, Italy and Spain, and the Nordics. For each organisation, we set out its core modality focus, its development and manufacturing capabilities, why it matters within the wider European landscape, and the leadership functions most relevant to partnership, business development and account-based marketing.

Whether you are a solution provider deciding where to focus commercial effort, a technology company scoping new accounts, or an investor building a picture of the European ecosystem, this guide gives you a working map of the organisations shaping the sector today.

What this guide includes

- Leading biopharmaceutical companies, CDMOs & academic institutes across seven European regions
- Core modality for each organisation
- Discovery, CMC, process development, formulation and manufacturing capabilities
- The strategic importance of each organisation within its region

80+

Biopharma Companies, CDMOs & Academics

7

Regional Sections

3

Company Categories

How to use this guide

- Identify high-priority target accounts by region and modality.
- Match your offering to relevant capabilities such as CMC, formulation, MSAT, API manufacturing, fill-finish or technology transfer.
- Compare developers, global pharma organisations and CDMOs across key European clusters.

A dynamic hub for RNA, peptide, vaccine, formulation, viral-vector and synthetic-DNA innovation.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
AstraZeneca	Global Pharma	UK	RNA, oligonucleotides, peptides	Discovery, CMC, formulation, manufacturing	Leading investor in next-generation oligonucleotide and peptide therapeutics across oncology and rare diseases.
GSK	Global Pharma	UK	Vaccines, RNA	Vaccines, CMC, drug product manufacturing	Global vaccines leader expanding nucleic-acid platforms and advanced manufacturing.
Quotient Sciences	CDMO	UK	Drug product manufacturing	Formulation, manufacturing	Integrated development partner supporting formulation through clinical supply.
Fujifilm Diosynth Biotechnologies	CDMO	UK	Biologics, viral vectors	Cell culture manufacturing, drug substance, MSAT	Major UK biologics campus supporting cell and gene therapy clients from process development through commercial supply.
Bicycle Therapeutics	Biotech	UK	Bicyclic peptides	Peptide discovery, engineering, clinical development	Pioneer of constrained bicyclic peptide therapeutics with an expanding precision-oncology pipeline.
SENISCA	Biotech	UK	RNA therapeutics	RNA biology, senescence modulation, preclinical development	Develops RNA-based approaches targeting cellular senescence and age-related disease mechanisms.
SynaptixBio	Biotech	UK	Antisense oligonucleotides	ASO discovery, rare-disease development, translational research	Advances antisense therapies for severe inherited neurological disorders with high unmet need.
Eleven Therapeutics	Biotech	UK	RNA therapeutics	AI-enabled RNA design, discovery, optimisation	Advances antisense therapies for severe inherited neurological disorders with high unmet need.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Silence Therapeutics	Biotech	UK	siRNA, oligonucleotides	siRNA discovery, GalNAc delivery, CMC, clinical development	A leading European RNAi developer advancing precision siRNA medicines through proprietary delivery technology.
Orthogonal Peptides	Biotech	UK	Peptides	Peptide design, synthesis, discovery	Develops differentiated peptide technologies and discovery approaches for hard-to-drug biological targets.
Orfonyx Bio	Biotech	UK	Peptides, biologics	Discovery, protein and peptide engineering, translational development	Applies engineered biological modalities to create differentiated therapeutics for complex disease targets.
Harness Therapeutics	Biotech	UK	RNA therapeutics	RNA biology, target discovery, preclinical development	Builds disease-modifying RNA medicines by restoring functional protein expression in neurological disease.
University of Nottingham	University	UK	Peptides, RNA, biologics	Discovery research, formulation, analytical science, translational development	Combines strong pharmaceutical-sciences research with peptide, RNA and drug-delivery expertise.
University of Oxford	University	UK	RNA, peptides, vaccines	Discovery, translational research, delivery, clinical development	A globally influential research hub generating advanced therapeutic platforms and spin-out companies.
University of Southampton	University	UK	Peptides, RNA, biologics	Drug discovery, immunology, analytical and translational research	Supports interdisciplinary therapeutic discovery across chemistry, medicine, immunology and bioengineering.
University of Kent	University	UK	Peptides, proteins	Protein science, peptide chemistry, bioprocess research	Provides specialist expertise in protein science, biomolecular engineering and therapeutic discovery.
University of Huddersfield	University	UK	Peptides, drug delivery	Medicinal chemistry, formulation, analytical development	Contributes applied pharmaceutical research in peptide chemistry, formulation and advanced drug delivery.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Imperial College London	University	UK	RNA, peptides, biologics	Discovery, bioengineering, delivery, translational research	A major source of advanced therapeutic innovation spanning RNA delivery, biomaterials and precision medicine.
Orthogonal Peptides	Biotech	UK	Peptides	Peptide design, synthesis, discovery	Develops differentiated peptide technologies and discovery approaches for hard-to-drug biological targets.
Arecor Therapeutics	Biotech	UK	Peptides, biologics	Formulation, protein stabilisation, drug product development	Uses proprietary formulation technology to improve stability, usability and delivery of complex medicines.
Almac Group	CDMO	UK	Peptides, oligonucleotides, drug product	API development, analytical services, formulation, clinical supply	Integrated CDMO supporting development, manufacturing and clinical supply across complex modalities.
Asymchem UK	CDMO	UK	Peptides, oligonucleotides, small molecules	Process development, API manufacturing, analytical development	Provides process R&D and scalable manufacturing support for complex APIs and emerging modalities.
Aurigene UK	CDMO	UK	Peptides, biologics, small molecules	Discovery, medicinal chemistry, development services	Supports global drug discovery and development programmes with integrated scientific capabilities.

IRELAND

A fast-growing manufacturing base where major US and European pharma companies are concentrating peptide and biologics capacity.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Eli Lilly	Global Pharma	Ireland	Peptides, biologics	Peptide API manufacturing, biologics drug substance	Multi-billion-euro manufacturing footprint spanning Kinsale and Limerick, combining advanced peptide platforms with growing biologics capacity.
Regeneron	Global Pharma	Ireland	Biologics	Bulk biologics drug substance manufacturing	One of Ireland's largest bulk biologics production sites, supplying commercial volumes across Regeneron's global portfolio.
Bristol Myers Squibb	Global Pharma	Ireland	Biologics	Cell culture manufacturing, sterile drug product	Large-scale Cruiserath biologics campus underpinning BMS's global oncology and immunology supply chain.
AstraZeneca (Ireland)	Global Pharma	Ireland	API manufacturing	Active pharmaceutical ingredient production	Dedicated Dublin API facility supporting AstraZeneca's expanding biopharmaceutical pipeline.

DACH (GERMANY, SWITZERLAND & AUSTRIA)

Europe's most concentrated cluster for mRNA, oligonucleotide, peptide, CMC, API and advanced-therapy manufacturing.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
BioNTech	Biotech	Germany	mRNA, immunotherapy	RNA manufacturing, LNP	Pioneer in mRNA therapeutics with an expanding oncology pipeline.
CureVac	Biotech	Germany	mRNA	RNA design, GMP manufacturing	Developer of mRNA medicines supported by proprietary RNA-optimisation technologies.
Lonza	CDMO	Switzerland	Peptides, oligos, bioconjugates	GMP, technology transfer, MSAT	Premier CDMO supporting clinical-to-commercial manufacturing.
Roche	Global Pharma	Switzerland	RNA, biologics	CMC, manufacturing	Global innovator with significant investment in advanced modalities.
Novartis	Global Pharma	Switzerland	RNA, gene therapy	Manufacturing, CMC	Broad advanced-therapy portfolio supported by a global manufacturing network.
Bayer	Global Pharma	Germany	Cell & gene, RNA	Process development	Expanding advanced-therapy manufacturing capabilities.
Boehringer Ingelheim	Global Pharma	Germany	Biologics	Bioprocess, manufacturing	Global biologics manufacturing leader with strong CMC capabilities.
Evotec	Biotech / CDMO	Germany	RNA, discovery	Discovery, development	Leading drug-discovery partner expanding RNA capabilities.
CordenPharma	CDMO	Switzerland	Peptides, oligos	API, GMP	Major European CDMO for peptide and oligonucleotide manufacturing.

DACH (GERMANY, SWITZERLAND & AUSTRIA)

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Rentschler Biopharma	CDMO	Germany	Biologics	Process development, GMP manufacturing	Long-established biologics CDMO with strong process development and technology transfer expertise.
Secarna Pharmaceuticals	Biotech	Germany	Antisense oligonucleotides	ASO discovery, target validation, preclinical development	Specialist antisense company advancing proprietary oligonucleotide medicines and partnered discovery programmes.
Isarna Therapeutics	Biotech	Germany	Antisense oligonucleotides	ASO development, ophthalmology, translational research	Develops antisense therapies targeting disease-driving growth factors in ophthalmic and fibrotic disorders.
Veraxa	Biotech	Germany	Bioconjugates, peptides	Antibody engineering, conjugation, targeted therapeutics	Builds next-generation targeted therapeutics using antibody engineering and precision bioconjugation platforms.
AiCuris	Biotech	Germany	RNA, antiviral therapeutics	Discovery, translational development, clinical development	A recognised anti-infectives innovator with deep expertise in viral biology and advanced therapeutic development.
Cardior Pharmaceuticals	Biotech	Germany	Non-coding RNA therapeutics	RNA discovery, cardiovascular translation, clinical development	Pioneers non-coding RNA medicines designed to address the molecular drivers of cardiovascular disease.
sterna biologicals GmbH	Biotech	Germany	DNAzymes, oligonucleotides	Nucleic-acid therapeutics, formulation, clinical development	Develops catalytic oligonucleotide therapies for inflammatory and immune-mediated diseases.
TU Berlin	University	Germany	Peptides, RNA, biologics	Bioengineering, chemistry, process development, analytics	Links engineering and life sciences to advance scalable bioprocesses and therapeutic technologies.
Freie Universität Berlin	University	Germany	Peptides, RNA, biologics	Molecular discovery, medicinal chemistry, translational research	A major biomedical research centre with strengths in molecular medicine and therapeutic discovery.

DACH (GERMANY, SWITZERLAND & AUSTRIA)

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Charité Berlin	University Hospital	Germany	RNA, peptides, advanced therapies	Clinical translation, biomarkers, early clinical development	One of Europe's largest university hospitals, connecting advanced therapeutic research with clinical validation.
Ulm University	University	Germany	Peptides, RNA, biologics	Molecular medicine, protein science, translational research	Contributes strong molecular-medicine and biomedical research capabilities to Germany's therapeutic ecosystem.
University Hospital Tübingen	University Hospital	Germany	RNA, peptides, advanced therapies	Translational medicine, clinical development, personalised therapies	A leading centre for translational medicine and precision therapeutics with close industry collaboration.
University of Göttingen	University	Germany	Peptides, RNA, proteins	Structural biology, molecular medicine, drug discovery	Internationally recognised for molecular biosciences, structural biology and translational therapeutic research.
Ella Biotech	CDMO	Germany	Oligonucleotides	Custom synthesis, purification, analytical services	Specialist oligonucleotide manufacturer supporting research and early development with tailored synthesis services.
BioSpring	CDMO	Germany	Oligonucleotides	Process development, GMP API manufacturing, analytics	Leading European oligonucleotide CDMO supporting programmes from development through commercial supply.
BianoGMP	CDMO	Germany	Oligonucleotides	Small- and medium-scale GMP manufacturing, process development	Specialised GMP partner for therapeutic oligonucleotides, particularly early clinical and smaller-batch programmes.
Axolabs	CDMO	Germany	Oligonucleotides, RNA	Discovery support, analytics, bioanalysis, CMC services	A specialist partner providing end-to-end scientific support for oligonucleotide and RNA therapeutic development.
HAYA Therapeutics	Biotech	Switzerland	Long non-coding RNA therapeutics	RNA discovery, precision medicine, preclinical development	Pioneers regulatory-genome medicines targeting disease-driving long non-coding RNAs.
Space Peptides	CDMO	Switzerland	Peptides	Discovery, process development, GMP manufacturing	Swiss-headquartered peptide CRDMO supporting programmes from discovery to commercial supply.

DACH (GERMANY, SWITZERLAND & AUSTRIA)

Company	Type	Country	Core Modality	Capabilities	Why They Matter
PharmaBlock	CDMO	Switzerland	Peptides, oligonucleotides, conjugates	Process chemistry, analytical development, GMP manufacturing	Integrated CRDMO expanding new-modality capabilities alongside scalable and lower-carbon manufacturing technologies.
PolyPeptide Group	CDMO	Switzerland	Peptides	Process development, GMP API manufacturing, commercial supply	Global peptide CDMO with extensive development and manufacturing capacity across clinical and commercial stages.

Shape the future of oligonucleotides and peptide therapeutics alongside the industry's brightest minds. Connect with world leaders in oligonucleotide and peptide innovation across **Oligos and Peptides Manufacturing DACH, Europe and APAC.**

Oligos & Peptides
Manufacturing Europe 2027

[REGISTER YOUR INTEREST](#)

co-located with

BIOLOGICS
MANUFACTURING
IRELAND 2027

ANTIBODY
ENGINEERING
&
ADC MANUFACTURING
EUROPE 2027

Oligos & Peptides
Manufacturing DACH 2027

[REGISTER YOUR INTEREST](#)

co-located with

CGT MANUFACTURING
DACH 2027

BIOLOGICS
MANUFACTURING DACH 2027

Oligos & Peptides
Manufacturing APAC 2027

[REGISTER YOUR INTEREST](#)

co-located with

CELL & GENE
THERAPY WORLD
ASIA 2027

BIOLOGICS
MANUFACTURING ASIA 2027

ADC ASIA
CONGRESS 2027

CLINICAL TRIALS
FESTIVAL ASIA 2027

BIOSUPPLY
CHAIN ASIA 2027

A strong ecosystem for biologics, antibody development, formulation and technical development.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
argenx	Biotech	Netherlands / Belgium	Biologics	CMC, technical development	Leader in antibody therapeutics with advanced development capabilities.
UCB	Global Pharma	Belgium	Biologics	Formulation, CMC	Expertise in biologics and injectable formulation development.
Janssen Pharmaceutica	Global Pharma	Belgium	Biologics, vaccines	CMC, manufacturing, formulation	Major biopharmaceutical hub within Johnson & Johnson's global manufacturing and vaccines network.
Ablynx (Sanofi)	Biotech	Belgium	Biologics (nanobodies)	Discovery, CMC	Pioneer of nanobody technology, now developed as part of Sanofi's biologics portfolio.

A strategic base for vaccines, RNA, peptide development and global pharmaceutical manufacturing.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Sanofi	Global Pharma	France	RNA, peptides	Drug product, vaccines	Global biopharma investing in RNA, vaccines and specialty medicines.
Ipsen	Global Pharma	France	Peptides	API manufacturing, formulation	Established peptide therapeutics leader with a growing specialty biologics pipeline.

A growing Southern European cluster for specialty pharma and biologics CDMO capacity.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Chiesi	Pharma	Italy	Biologics	Manufacturing, CMC	Specialty pharma expanding biologics and advanced-therapy capabilities.
mAbxience	CDMO	Spain	Biologics	Biosimilar and CDMO manufacturing, cell line development	Leading Spanish biologics CDMO operating Europe's largest single-use manufacturing facility for biosimilars.
Kither Biotech	Biotech	Italy	Peptides	Peptide therapeutics, pulmonary delivery, clinical development	Develops disease-modifying peptide medicines for respiratory disorders with significant unmet need.
CIRPeB / Naples	Research Centre	Italy	Peptides	Peptide chemistry, synthesis, structural and biological research	A specialist peptide research centre supporting discovery, characterisation and academic-industry collaboration.
PeptLab / University of Florence	University Lab	Italy	Peptides	Peptide synthesis, medicinal chemistry, structural studies	Provides specialised peptide-design and synthesis expertise for therapeutic and diagnostic innovation.
Olon S.p.A.	CDMO	Italy	Peptides, oligonucleotides, APIs	Process development, GMP API manufacturing, scale-up	Large global API CDMO investing in complex chemistry and emerging-modality manufacturing.
Chemi Peptides	CDMO	Italy	PeptidPeptides es, complex APIs	Peptide API development, synthesis, GMP manufacturing	Specialist peptide manufacturer supporting clinical and commercial API requirements.
Indena	CDMO	Italy	Peptides, complex APIs	Process development, analytical services, GMP manufacturing	Established Italian development and manufacturing partner with expertise in complex active ingredients.
Peptomyc	Biotech	Spain	Cell-penetrating peptides	Peptide discovery, oncology, preclinical and clinical development	Develops first-in-class cell-penetrating peptide therapeutics targeting previously undruggable oncology pathways.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
ARTHEX Biotech	Biotech	Spain	Antisense oligonucleotides	ASO discovery, rare-disease development, translational research	Advances antisense medicines for neuromuscular and rare diseases through a proprietary RNA-targeting platform.
3PBIOVIAN	CDMO	Spain	Biologics, RNA, viral vectors	Process development, GMP manufacturing, fill-finish	Integrated Spanish CDMO supporting biologics and advanced therapies from development to commercial manufacture.
CIMA Universidad de Navarra	Research Centre	Spain	RNA, peptides, biologics	Discovery, translational medicine, clinical research	A major Spanish biomedical centre connecting molecular discovery with translational and clinical development.
IQAC-CSIC	Research Institute	Spain	Peptides, oligonucleotides, chemical biology	Synthesis, analytical chemistry, delivery and molecular design	A leading chemistry institute advancing nucleic-acid, peptide and delivery technologies through interdisciplinary research.
University of Barcelona	University	Spain	Peptides, RNA, biologics	Drug discovery, formulation, analytical and translational research	One of Spain's largest research universities with broad capabilities across pharmaceutical and biomedical sciences.
Sylentis	Biotech	Spain	siRNA, oligonucleotides	RNAi discovery, delivery, clinical development	A Spanish RNAi pioneer and coordinator of OLIGOFASTX, advancing gene-silencing therapeutics.
AptaTargets	Biotech	Spain	RNA aptamers	Aptamer discovery, preclinical and clinical development	Develops therapeutic RNA aptamers for acute and high-unmet-need diseases.
Nanovex Biotechnologies	Biotech	Spain	RNA delivery, nanomedicine	Nanoparticle formulation, delivery systems, scale-up	Develops nanotechnology platforms designed to improve delivery and performance of advanced therapeutics.
Nostrum Biodiscovery	Biotech	Spain	Computational RNA and drug discovery	AI, molecular modelling, design and optimisation	Uses advanced computational chemistry and AI to accelerate design and optimisation of therapeutic candidates.
Aptus Biotech	Biotech	Spain	Aptamers, oligonucleotides	Aptamer selection, optimisation, diagnostic and therapeutic development	Specialises in aptamer technologies for targeted therapeutics, diagnostics and molecular recognition.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
BCN Peptides	CDMO	Spain	Peptides	Peptide synthesis, process development, GMP manufacturing	Spanish peptide CDMO offering development and manufacturing services for clinical and commercial programmes.
53Biologics	CDMO	Spain	Oligonucleotides, biologics	Process development, analytics, GMP manufacturing	OLIGOFASTX partner contributing process-development and manufacturing expertise for oligonucleotide therapies.

A world-class centre for peptide therapeutics, sterile manufacturing, biologics development and GMP production.

Company	Type	Country	Core Modality	Capabilities	Why They Matter
Novo Nordisk	Pharma	Denmark	Peptides	API, manufacturing	World leader in peptide therapeutics for metabolic disease.
Zealand Pharma	Biotech	Denmark	Peptides	CMC, discovery	Specialist in peptide therapeutics with a strong metabolic pipeline.
Recipharm	CDMO	Sweden	Sterile, drug product	Fill-finish	Global CDMO with sterile-manufacturing expertise.
AGC Biologics	CDMO	Denmark	Biologics	Development, GMP	End-to-end biologics CDMO supporting cell line development through commercial supply.
University of Gothenburg	University	Sweden	Peptides, RNA, biologics	Discovery, translational medicine, analytical science	A leading Nordic biomedical university with strong translational research and therapeutic-discovery capabilities.
University of Copenhagen	University	Denmark	Peptides, RNA, biologics	Drug discovery, formulation, structural and translational research	A major European life-sciences hub with deep expertise in peptide science and pharmaceutical development.
Aarhus University	University	Denmark	Peptides, proteins, RNA	Molecular medicine, structural biology, translational research	Combines strong molecular bioscience and clinical research capabilities across advanced therapeutic modalities.
University of Southern Denmark	University	Denmark	Peptides, proteins, drug delivery	Protein science, medicinal chemistry, formulation research	Recognised for interdisciplinary pharmaceutical, protein and molecular-medicine research.

Key terms and functions used throughout this eBook

CMC: Chemistry, Manufacturing and Controls activities supporting product quality, development and regulatory readiness.

MSAT: Manufacturing Science and Technology: the bridge between process development, technology transfer and routine manufacturing.


CDMO: Contract Development and Manufacturing Organisation.

LNP: Lipid nanoparticle delivery technology commonly used for RNA medicines.

API: Active Pharmaceutical Ingredient.

Priority leadership functions

- Chief Scientific Officer / Head of R&D
- SVP / VP CMC
- Head of Pharmaceutical or Technical Development
- Head of Process Development
- Head of Drug Product or Formulation
- Head of Manufacturing / Operations
- Head of MSAT / Technology Transfer
- Head of Quality / Analytical Development
- Head of Supply Chain / Product Supply



2026 -2027 Event Calendar

VISIT OUR WEBSITE